Lanean...

Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer

OBJECTIVE: To evaluate the efficacy and safety of icotinib hydrochloride in patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 89 patients with stage IIIB or IV NSCLC received icotinib at a dose of 125 mg administered 3 times a day. Icotinib treatment was continued until...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Gu, Aiqin, Shi, Chunlei, Xiong, Liwen, Chu, Tianqing, Pei, Jun, Han, Baohui
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2013
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3555305/
https://ncbi.nlm.nih.gov/pubmed/23372346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2012.12.07
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!